ArticleJournal of mammary gland biology and neoplasia2025
Association of ESR1, HER1, and HER2 Polymorphisms with Breast Cancer Risk in the KP Population, A Case-Control Study.
Article in Journal of mammary gland biology and neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Role ofHealth science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a complex disease characterized by the uncontrolled growth of breast cells. Genetic variants in ESR1, HER1, and HER2 have been associated with breast cancer risk across different populations, with varying results. This study aimed to validate the association of ESR1 (rs2234693 and rs2046210), HER1 (rs11543848), and HER2 (rs1136201) variants with breast cancer risk in the KP population of Pakistan using a larger dataset. The study cohort included 528 patients with BC and 530 healthy controls. Blood samples were collected, and DNA was extracted using a non-enzymatic method. Genotyping was performed using the T-ARMS-PCR protocol. Our results for ESR1 (rs2234693) indicated a non-significant association between the mutant C allele (P = 0.102), TC (P = 0.1002), and CC genotype (P = 0.398) and breast cancer risk. In contrast, ESR1 and rs2046210 showed a significant association with the mutant A allele (P = 0.001), GA (P = 0.001), and AA genotype (P = 0.001), indicating an increased risk. HER1 and rs11543848 showed an increased risk of breast cancer, with the mutant allele A (P = 0.001), GA (P = 0.001), and AA genotype (P = 0.001). Similarly, alleles G (P = 0.004), AG (P = 0.001), and GG genotype (P = 0.003) of HER2 (rs1136201) were associated with higher breast cancer risk. Furthermore, ESR1 (rs2234693) was significantly associated with PR status, while both HER1 (rs11543848) and HER2 (rs1136201) were considerably associated with HER2 receptor status. In conclusion, this study explored the association of the selected variants of ESR1, HER1, and HER2 with breast cancer risk in the KP population using a larger data set, providing valuable insights into the genetic factors contributing to breast cancer risk and corresponding value added to breast cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.